Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).

被引：4
|
作者：
Quintela-Fandino, Miguel
Apala, Juan V.
Salgado, Alfonso Cortes
Mouron, Silvana Andrea
Guerra, Juan Antonio
Cortes, Mana Gion
Morente, Manuel
Manso, Luis
机构：
[1] CNIO Spanish Natl Canc Res Ctr, Madrid, Spain
[2] CNIO, Madrid, Spain
[3] Hosp Ramon & Cajal, Madrid, Spain
[4] Spanish Natl Canc Res CNIO, Breast Canc Clin Res Unit, Madrid, Spain
[5] Hosp Fuenlabrada, Madrid, Spain
[6] Hosp 12 Octubre, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2552
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C.
    Gligorov, J.
    Marschner, N.
    Puglisi, F.
    Vrdoljak, E.
    Castan, J. Cortes
    de Ducla, S.
    Deurloo, R.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
    Yardley, Denise A.
    Bosserman, Linda D.
    O'Shaughnessy, Joyce A.
    Harwin, William N.
    Morgan, Susan K.
    Priego, Victor M.
    Peacock, Nancy W.
    Bass, J. David
    Burris, Howard A., III
    Hainsworth, John D.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (01) : 89 - 97
  • [33] Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
    Denise A. Yardley
    Linda D. Bosserman
    Joyce A. O’Shaughnessy
    William N. Harwin
    Susan K. Morgan
    Victor M. Priego
    Nancy W. Peacock
    J. David Bass
    Howard A. Burris III
    John D. Hainsworth
    Breast Cancer Research and Treatment, 2015, 154 : 89 - 97
  • [34] CNIO-BR-009 trial: Targeting mitochondrial metabolism with ME-344 in breast cancer upon bevacizumab-induced vascular normalization: A phase 0 randomized clinical trial
    Cortes, Alfonso
    Victor Apala, Juan
    Malon, Diego
    Guerra, Juan
    Gion-Cortes, Maria
    Manso, Luis
    Hornedo, Javier
    Gonzalez-Cortijo, Lucia
    Mouron, Silvana
    Quintela-Fandino, Miguel
    CANCER RESEARCH, 2018, 78 (04)
  • [35] A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)
    Baselga, J.
    Zamagni, C.
    Gomez, P.
    Bermejo, B.
    Nagai, S.
    Melichar, B.
    Chan, A.
    Mangel, L.
    Bergh, J.
    Costa, F. P.
    Gomez, H. L.
    Gradishar, W.
    Hudis, C. A.
    Rapoport, B.
    Roche, H.
    Maeda, P.
    Huang, L.
    Zhang, J.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2014, 25
  • [36] SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)
    Lang, I.
    Inbar, M.
    Greil, R.
    Kahan, Z.
    Beslija, S.
    Steger, G. G.
    Stemmer, S. M.
    Zvribule, Z.
    Kaufman, B.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
  • [37] Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C. C.
    Lang, I.
    Inbar, M.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Zvirbule, Z.
    Steger, G. G.
    Melichar, B.
    Pienkowski, T.
    Sirbu, D.
    Petruzelka, L.
    Eniu, A.
    Nisenbaum, B.
    Dank, M.
    Anghel, R.
    Messinger, D.
    Brodowicz, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S263 - S264
  • [38] Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial
    Ishikawa, T.
    Akazawa, K.
    Hasegawa, Y.
    Tanino, H.
    Horiguchi, J.
    Miura, D.
    Hayashi, M.
    Takao, S.
    Kim, S. J.
    Yamagami, K.
    Miyashita, M.
    Konishi, M.
    Shigeoka, Y.
    Suzuki, M.
    Taguchi, T.
    Kubota, T.
    Kohno, N.
    CANCER RESEARCH, 2017, 77
  • [39] Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
    Miles, David
    Cameron, David
    Bondarenko, Igor
    Manzyuk, Lyudmila
    Alcedo, Juan Carlos
    Lopez, Roberto Ivan
    Im, Seock-Ah
    Canon, Jean-Luc
    Shparyk, Yaroslav
    Yardley, Denise A.
    Masuda, Norikazu
    Ro, Jungsil
    Denduluri, Neelima
    Hubeaux, Stanislas
    Quah, Cheng
    Bais, Carlos
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2017, 70 : 146 - 155
  • [40] Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer
    Miles, David
    Cameron, David
    Hilton, Magalie
    Garcia, Josep
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2018, 90 : 153 - 155
12345